These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 6858446)

  • 1. [Effect of marking laboratory animals on the results of pertussis vaccine potency tests].
    Freudenstein H; Körner L
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Feb; 253(4):554-8. PubMed ID: 6858446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of pertussis serological potency test. Serological assessment of antibody response induced by whole cell vaccine as an alternative to mouse protection in an intracerebral challenge model.
    van der Ark A; van Straaten-van de Kappelle I; Akkermans A; Hendriksen C; van de Donk H
    Biologicals; 1994 Sep; 22(3):233-42. PubMed ID: 7811457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.
    Gaines-Das R; Horiuchi Y; Zhang SM; Newland P; Kim Y; Corbel M; Xing D
    Vaccine; 2009 Nov; 27(49):6824-32. PubMed ID: 19765397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of an aerosol challenge model as alternative to the intracerebral mouse protection test for potency assay of whole cell pertussis vaccines.
    Canthaboo C; Xing D; Douglas A; Corbel M
    Biologicals; 2000 Dec; 28(4):241-6. PubMed ID: 11237360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A respiratory challenge model for infection with Bordetella pertussis: application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity.
    Mills KH; Brady M; Ryan E; Mahon BP
    Dev Biol Stand; 1998; 95():31-41. PubMed ID: 9855412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pertussis whole cell and acellular vaccines on pulmonary immunology in an aerosol challenge model.
    Carter CR; Dagg BM; Whitmore KM; Keeble JR; Asokanathan C; Xing D; Walker KB
    Cell Immunol; 2004 Jan; 227(1):51-8. PubMed ID: 15051514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.
    Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR
    Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pertussis Serological Potency Test. Collaborative study to evaluatereplacement of the Mouse Protection Test.
    van der Ark A; van Straaten-van de Kappelle I; Olander RM; Enssle K; Jadhav S; van de Donk H; Hendriksen C
    Biologicals; 2000 Jun; 28(2):105-18. PubMed ID: 10885617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of a Bordetella pertussis patient isolated strain and classical strains used in the pertussis vaccine.
    Pereira A; Pereira AS; Moreira-Filho CA; Bando SY; Tambourgi DV
    Vaccine; 2005 Jul; 23(34):4353-8. PubMed ID: 16005744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developments in reduction and replacement of in vivo toxicity and potency tests for pertussis vaccines.
    Xing D; Canthaboo C; Douglas-Bardsley A; Yuen CT; Prior S; Liu Y; Corbel M
    Dev Biol (Basel); 2002; 111():57-68. PubMed ID: 12678225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model.
    Denoël P; Godfroid F; Guiso N; Hallander H; Poolman J
    Vaccine; 2005 Nov; 23(46-47):5333-41. PubMed ID: 16054273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertussis serological potency test as an alternatively to the intracerebral mouse protection test.
    van der Ark A; van Straaten-van de Kappelle I; Hendriksen C; van de Donk H
    Dev Biol Stand; 1996; 86():271-81. PubMed ID: 8785956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the cellular pertussis vaccine: increased potency and consistency.
    Thalen M; van der Ark A; van den Ijssel J; van Straaten I; Jansen D; Beuvery C; Martens D; Tramper J
    Vaccine; 2008 Jan; 26(5):653-63. PubMed ID: 18155325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency tests for pertussis vaccines: doubtful value of intracerebral challenge test in mice.
    Preston NW
    J Pathol Bacteriol; 1966 Jan; 91(1):173-9. PubMed ID: 5941389
    [No Abstract]   [Full Text] [Related]  

  • 15. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin.
    Peppoloni S; Pizza M; De Magistris MT; Bartoloni A; Rappuoli R
    Physiol Chem Phys Med NMR; 1995; 27(4):355-61. PubMed ID: 8768791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a nitric oxide induction assay as a potential replacement for the intracerebral mouse protection test for potency assay of pertussis whole cell vaccines.
    Canthaboo C; Xing D; Corbel M
    Dev Biol Stand; 1999; 101():95-103. PubMed ID: 10566781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children.
    Mahon BP; Brady MT; Mills KH
    J Infect Dis; 2000 Jun; 181(6):2087-91. PubMed ID: 10837200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification methods in newborn C57BL/6 mice: a developmental and behavioural evaluation.
    Castelhano-Carlos MJ; Sousa N; Ohl F; Baumans V
    Lab Anim; 2010 Apr; 44(2):88-103. PubMed ID: 19854756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of DTP and Haemophilus influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity.
    Redhead K; Sesardic D; Yost SE; Attwell AM; Watkins J; Hoy CS; Plumb JE; Corbel MJ
    Biologicals; 1994 Dec; 22(4):339-45. PubMed ID: 7779360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant and immunogenic activities of the 73kDa N-terminal alpha-domain of BrkA autotransporter and Cpn60/60kDa chaperonin of Bordetella pertussis.
    Cainelli Gebara VC; Risoléo L; Lopes AP; Ferreira VR; Quintilio W; Lépine F; Silva WD; Raw I
    Vaccine; 2007 Jan; 25(4):621-9. PubMed ID: 17011680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.